NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 605.22M | 577.74M | 549.96M | 525.66M | 509.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 605.22M | 577.74M | 549.96M | 525.66M | 509.34M |
| Cost of Revenue | 136.18M | 135.47M | 132.19M | 131.56M | 127.54M |
| Gross Profit | 469.05M | 442.26M | 417.77M | 394.10M | 381.80M |
| SG&A Expenses | 427.21M | 382.06M | 381.98M | 386.89M | 386.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 772.76M | 727.93M | 726.31M | 731.06M | 735.49M |
| Operating Income | -167.54M | -150.19M | -176.34M | -205.40M | -226.16M |
| Income Before Tax | -131.16M | -114.49M | -141.13M | -172.30M | -191.74M |
| Income Tax Expenses | 37.47M | 35.29M | 27.57M | 20.44M | 15.30M |
| Earnings from Continuing Operations | -168.63 | -149.78 | -168.70 | -192.74 | -207.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -168.63M | -149.78M | -168.70M | -192.74M | -207.04M |
| EBIT | -167.54M | -150.19M | -176.34M | -205.40M | -226.16M |
| EBITDA | -157.67M | -140.61M | -166.42M | -195.61M | -216.46M |
| EPS Basic | -1.56 | -1.39 | -1.57 | -1.81 | -1.95 |
| Normalized Basic EPS | -0.90 | -0.78 | -0.93 | -1.11 | -1.24 |
| EPS Diluted | -1.56 | -1.39 | -1.57 | -1.81 | -1.95 |
| Normalized Diluted EPS | -0.90 | -0.78 | -0.93 | -1.11 | -1.24 |
| Average Basic Shares Outstanding | 431.69M | 430.20M | 428.72M | 427.31M | 425.71M |
| Average Diluted Shares Outstanding | 431.69M | 430.20M | 428.72M | 427.31M | 425.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |